Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

AI-Driven Drug Firm METiS Eyes $200 Million Hong Kong IPO Amid Growing Biotech Momentum

by Team Lumida
May 12, 2025
in AI
Reading Time: 4 mins read
A A
0
AI Investment Boom: How Tech Giants Are Leading the Charge

"Machine Learning & Artificial Intelligence" by mikemacmarketing is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • METiS Pharmaceuticals, an AI-driven drug discovery and delivery firm, is considering a Hong Kong IPO to raise up to $200 million by the end of 2025.
  • The company has raised $300 million in funding since its inception in 2020, with notable backers like CICC Capital, China Taiping Insurance, and HongShan (formerly Sequoia China).
  • METiS operates globally, with offices in Hangzhou, Beijing, Shanghai, and Cambridge, Massachusetts.
  • The IPO reflects growing investor interest in AI-powered biotech solutions, despite ongoing market uncertainties.

What Happened?

METiS Pharmaceuticals, a Hangzhou-based AI-driven drug discovery and delivery company, is reportedly planning an initial public offering (IPO) in Hong Kong to raise as much as $200 million. The company is working with advisers to finalize the IPO, which could take place before the end of 2025. While details such as the size and timing of the offering are still under discussion, METiS has not commented on the matter.

Since its founding in 2020, METiS has raised $300 million in funding, including a $100 million Series C round in June 2023 led by CICC Capital and supported by China Taiping Insurance and HongShan. The company has a global presence, with offices in China and the US.


Why It Matters?

METiS’s potential IPO highlights the growing intersection of artificial intelligence and biotechnology, a sector that has attracted significant investor interest due to its potential to revolutionize drug discovery and delivery. The $200 million IPO would provide METiS with additional capital to expand its operations and accelerate its AI-driven drug development initiatives.

The move also underscores Hong Kong’s appeal as a hub for biotech IPOs, particularly for Chinese firms seeking to tap into global capital markets. Despite broader market uncertainties, the biotech sector remains resilient, with investors drawn to its long-term growth potential.


What’s Next?

If METiS proceeds with the IPO, investors should monitor the company’s valuation, financial performance, and pipeline of AI-driven drug solutions. The success of the IPO could set a precedent for other AI-focused biotech firms considering public listings.

Additionally, the broader market environment, including geopolitical tensions and regulatory developments in Hong Kong, will play a critical role in shaping the outcome of this offering. Investors should also watch for updates on METiS’s partnerships and advancements in its drug discovery platform.

Source
Previous Post

US-China Tariff Reductions Signal Temporary Trade Truce, Markets React Positively

Next Post

Citi Predicts Stablecoins Will Expand Beyond Crypto, Reaching $1.6 Trillion by 2030

Recommended For You

OpenAI’s Golden Touch Spreads as Stocks Soar

by Team Lumida
5 hours ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways Powered by lumidawealth.com OpenAI’s annual developers event triggered sharp stock gains for publicly traded companies mentioned as partners or integrators, including Figma (+7.4%), HubSpot (+2.6%), Salesforce (+2.3%),...

Read more

How AMD Came From Behind to Mount a Challenge in the AI Chip Wars

by Team Lumida
5 hours ago
black and green lenovo logo

Key Takeaways Powered by lumidawealth.com AMD’s market value surged from under $3 billion in 2014 to over $330 billion today, driven by a strategic pivot from gaming and PC...

Read more

Elon Musk Gambles Billions in Memphis to Catch Up on AI

by Team Lumida
1 day ago
Major Tech Platforms Face Malaysian Licensing Deadline as X and Google Hold Out

Key Takeaways Powered by lumidawealth.com Elon Musk’s xAI is rapidly scaling its Memphis footprint with “Colossus” data centers; Colossus 2 aims for ~550,000 Nvidia chips (xAI has signaled potential...

Read more

OpenAI Announcements Ripple Through Public Markets

by Team Lumida
1 day ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways Powered by lumidawealth.com OpenAI’s product moves (DevDay, ChatGPT instant‑buy, Sora, internal AI tools) are driving notable re‑rating across public equities despite the company remaining private and uninvestable...

Read more

OpenAI Reverses Sora Copyright Stance

by Team Lumida
3 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways Powered by lumidawealth.com OpenAI changed Sora’s policy: copyrighted characters will require rightsholders to opt in (similar to public‑figure likenesses) and rightsholders will get new controls; earlier messaging...

Read more

BlackRock/GIP Nears $40B Takeover of Aligned Data Centers

by Team Lumida
4 days ago
Is BlackRock the New Leader in Alternative Investments?

Key Takeaways Powered by lumidawealth.com BlackRock’s Global Infrastructure Partners (GIP) is in advanced talks to acquire Aligned Data Centers for about $40 billion; Macquarie, Mubadala/MGX and other investors are...

Read more

Is AI Driving a Productivity Revival?

by Team Lumida
4 days ago
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

Key Takeaways Powered by lumidawealth.com U.S. GDP models (Atlanta Fed) estimate Q3 annualized growth near 3.8% while employment barely rose — implying a sharp lift in measured labor productivity...

Read more

Microsoft Folds AI Service Into Office

by Team Lumida
5 days ago
Microsoft’s Blue Screen of Death: What You Need to Know

Key Takeaways Powered by lumidawealth.com Microsoft is folding its consumer AI subscription into Microsoft 365 by launching a new Microsoft 365 Premium tier at $19.99/month that bundles an integrated...

Read more

Apple Shelves Vision Pro Overhaul to Prioritize Meta‑Style Smart Glasses

by Team Lumida
5 days ago
Apple Store shop front

Key Takeaways Powered by lumidawealth.com Apple paused a planned major revamp of Vision Pro (N100) and is reallocating staff to accelerate development of smart glasses. Two glass projects: an...

Read more

OpenAI Valuation Jumps to $500B After $6.6B Secondary Sale

by Team Lumida
5 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways Powered by lumidawealth.com OpenAI arranged a secondary sale valuing the company at ~$500 billion; current and former employees sold roughly $6.6 billion of stock to investors including...

Read more
Next Post
Bitcoin Plunges to $64K Amid U.S. Tech Stock Turmoil

Citi Predicts Stablecoins Will Expand Beyond Crypto, Reaching $1.6 Trillion by 2030

Can Apple’s Vision Pro Bounce Back with a Budget-Friendly Model?

Apple Weighs iPhone Price Hikes Amid Trade Risks and Supply Chain Shifts

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Is the AI Tech Rally at Risk? Two Major Red Flags Investors Can’t Ignore

Is the AI Tech Rally at Risk? Two Major Red Flags Investors Can’t Ignore

July 8, 2024
China’s Bold Economic Moves: What You Need to Know Now

China Cuts Rates and Injects $139 Billion in Liquidity to Counter U.S. Tariffs

May 7, 2025
man wearing academic gown

Elite Colleges Too Expensive for Middle-Class Families, Even at $300,000 Income

April 27, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018